Amgen Reports Third Quarter Earnings

Amgen (NASDAQ: AMGN) reported third quarter EPS of $5.58, which is $0.47 better than the analyst estimate of $5.11. Revenue for the quarter reached $8.5B, slightly below the consensus estimate of $8.51B.

Guidance

Amgen projects FY 2024 EPS of $19.20-$20.00 compared to the analyst consensus of $19.51.

Anticipated FY 2024 revenue is between $33.00B-$33.80B, against the analyst consensus of $33.20B.

Amgen's stock closed at $315.54, down 5.52% over the last three months but up 23.40% over the last year.

In the past 90 days, Amgen saw 8 positive EPS revisions and 11 negative EPS revisions. For past market reactions to earnings, check here.

According to InvestingPro, Amgen's Financial Health score is rated as "good performance".

For upcoming earnings reports, visit Investing.com's earnings calendar.